These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 29482122)
1. Evaluation of a method for measuring the radioprotective metabolite WR-1065 in plasma using chemical derivatization combined with UHPLC-MS/MS. Simon ES; Reyna D; Lister RJ; Harteg C; Lipka E J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Mar; 1080():82-89. PubMed ID: 29482122 [TBL] [Abstract][Full Text] [Related]
2. Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration. Ranganathan K; Simon E; Lynn J; Snider A; Zhang Y; Nelson N; Donneys A; Rodriguez J; Buchman L; Reyna D; Lipka E; Buchman SR Pharm Res; 2018 Mar; 35(5):99. PubMed ID: 29556791 [TBL] [Abstract][Full Text] [Related]
3. High-performance liquid chromatographic assay using electrochemical detection for the combined measurement of amifostine, WR 1065 and the disulfides in plasma. Korst AE; Vermorken JB; van der Vijgh WJ J Chromatogr B Biomed Sci Appl; 1997 May; 693(1):167-74. PubMed ID: 9200531 [TBL] [Abstract][Full Text] [Related]
4. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys. Bachy CM; Fazenbaker CA; Kifle G; McCarthy MP; Cassatt DR Oncology; 2004; 67(3-4):187-93. PubMed ID: 15557777 [TBL] [Abstract][Full Text] [Related]
5. Measurement of both protein-bound and total S-2-(3-aminopropylamino)ethanethiol (WR-1065) in blood by high-performance liquid chromatography. Bonner HS; Shaw LM J Chromatogr B Biomed Sci Appl; 2000 Mar; 739(2):357-62. PubMed ID: 10755379 [TBL] [Abstract][Full Text] [Related]
6. Effects of dose and schedule on the efficacy of ethyol: preclinical studies. Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient. Korst AE; Gall HE; Vermorken JB; van der Vijgh WJ Cancer Chemother Pharmacol; 1996; 39(1-2):162-6. PubMed ID: 8995515 [TBL] [Abstract][Full Text] [Related]
9. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine. Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM Semin Oncol; 2002 Dec; 29(6 Suppl 19):2-8. PubMed ID: 12577236 [TBL] [Abstract][Full Text] [Related]
10. Determination of WR-1065 in human blood by high-performance liquid chromatography following fluorescent derivatization by a maleimide reagent ThioGlo3. Chen J; Lu Z; Lawrence TS; Smith DE J Chromatogr B Analyt Technol Biomed Life Sci; 2005 May; 819(1):161-7. PubMed ID: 15797534 [TBL] [Abstract][Full Text] [Related]
12. Analysis of S-35 labeled WR-2721 and its metabolites in biological fluids. Anderson KW; Krohn KA; Grunbaum Z; Phillips RB; Mahler PA; Menard TW; Spence AM; Rasey JS Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1511-5. PubMed ID: 6090353 [TBL] [Abstract][Full Text] [Related]
13. Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure. Cassatt DR; Fazenbaker CA; Bachy CM; Kifle G; McCarthy MP Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):901-7. PubMed ID: 15708273 [TBL] [Abstract][Full Text] [Related]
14. Measurement of WR-2721, WR-1065, and WR-33278 in plasma. Fahey RC; Newton GL Int J Radiat Oncol Biol Phys; 1985 Jun; 11(6):1193-7. PubMed ID: 2987166 [TBL] [Abstract][Full Text] [Related]
15. A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy. Feng M; Smith DE; Normolle DP; Knol JA; Pan CC; Ben-Josef E; Lu Z; Feng MR; Chen J; Ensminger W; Lawrence TS Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1441-7. PubMed ID: 22440042 [TBL] [Abstract][Full Text] [Related]
16. Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine. Levi M; DeRemer SJ; Dou C; Ensminger WD; Smith DE Biopharm Drug Dispos; 2004 Jan; 25(1):27-35. PubMed ID: 14716750 [TBL] [Abstract][Full Text] [Related]
17. Feasibility study of the pharmacology of local application of amifostine (WR-2721) to the buccal mucosa in guinea pigs. Li C; Wang S; Huang T; Chen N; Ou M Pharmacology; 2013; 91(5-6):281-6. PubMed ID: 23736649 [TBL] [Abstract][Full Text] [Related]
18. Determination of the cytoprotective agent WR-2721 (Amifostine, Ethyol) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography. Souid AK; Newton GL; Dubowy RL; Fahey RC; Bernstein ML Cancer Chemother Pharmacol; 1998; 42(5):400-6. PubMed ID: 9771955 [TBL] [Abstract][Full Text] [Related]
19. Radioprotection in mice following oral administration of WR-1065/PLGA nanoparticles. Pamujula S; Kishore V; Rider B; Agrawal KC; Mandal TK Int J Radiat Biol; 2008 Nov; 84(11):900-8. PubMed ID: 19016138 [TBL] [Abstract][Full Text] [Related]
20. Enteral Activation of WR-2721 Mediates Radioprotection and Improved Survival from Lethal Fractionated Radiation. Molkentine JM; Fujimoto TN; Horvath TD; Grossberg AJ; Garcia CJG; Deorukhkar A; de la Cruz Bonilla M; Lin D; Samuel ELG; Chan WK; Lorenzi PL; Piwnica-Worms H; Dantzer R; Tour JM; Mason KA; Taniguchi CM Sci Rep; 2019 Feb; 9(1):1949. PubMed ID: 30760738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]